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Abstract
Background: Tenofovir is a widely used antiviral drug for the treatment of HIV and HBV infection. Although its side
effects on renal function and bone metabolism are well known, there are no reports on focal bone lesions caused
by this drug. Our case suggests this new, unusual but important scenario.
Case presentation: We report on a 46-year-old HIV-positive man treated with an antiretroviral regimen containing
tenofovir who suddenly developed localized inflammatory bone lesions. The examinations performed ruled out all
the disorders commonly associated with this clinical pattern, and the patient’s conditions improved only after the
suspension of tenofovir.
Conclusions: The case study suggests a rare but severe adverse event, which should be taken into account when
physicians treat HIV-positive patients with focal inflammatory bone lesions
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Background
Tenofovir (TDF) is an antiviral drug widely used as first-
line therapy in HIV infection and prophylaxis as well
as in HBV infection [1]. It is frequently chosen for its
efficacy and its ease of use in the once-daily single-tablet
regimens [1,2]. However, it has been clearly associated
with renal toxicity [3] and with a decrease in Bone Mineral
Density (BMD) [4]. Metabolic bone diseases are often an
issue in patients with HIV infection: the prevalence of
osteoporosis-associated fractures has been found to be
60% higher in HIV-infected patients as compared with
HIV-uninfected persons, with a 6.4 fold increased odds of
osteopenia and 3.7-fold increased odds of osteoporosis
[5]. Important pathogenic roles have been identified in
the virus itself, in the immune activation triggered by
HIV [6], in individual risk factors (such as sex, age, low
BMI, smoking, alcohol abuse, HCV coinfection) and in
drug toxicities, particularly from TDF [7]. Nevertheless,
there is no report in the literature about focal bone
damages in HIV-infected patients due to this drug.
Case presentation
We report on a 46-year-old homosexual man who has
been HIV seropositive since 1994, with a history of
multiple undiagnosed episodes of osteo-articular pain
with no elective localizations and always resolving after
the assumption of non-steroidal anti-inflammatory drugs.
The patient's HAART regimen was tenofovir-entricitabine
and lopinavir/ritonavir since 2008. He was also treated
with fenofibrate and amisulpride at low dosage (50 mg 1
tablet QD). His viral load was undetectable since 2003,
and the CD4+ T cell count 466 cells/μL in the last blood
test before the time of this report. In April 2011 the
patient performed lumbar spine and femoral neck DEXA
(Dual-Energy X-ray Absorptiometry) for osteopenia screen-
ing. Lumbar spine DEXA showed: BMD = 1.043 g/cm2,
T-score = -0.4, Z-score = -0.2; in the femoral neck DEXA:
BMD= 0.868 g/cm2, T-score = -0.5, Z-score = 0.2. All of
these values were within their normal limits.
Two months later, the patient came to our Clinic after
4 weeks of remittent fever with peaks of 38°C and signs
of inflammation and progressive joint pain in the left
lower limb. He was hospitalized and we carried out first
level examinations: lower limbs x-ray and doppler ultra-
sound ruled out bone fractures and deep vein thrombosis.
Multiple blood cultures resulted negative, while the
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markers of inflammation were elevated (ESR: 68 mm/h,
normal range: 0-15; CRP: 9.24 mg/dL, normal range <
0.50). Interestingly, the x-ray images showed a focal
bone loss localized in the left tibia [Figure 1 Panel A].
Subsequently, the following laboratory test were performed:
autoimmunity screening panel (Anti-Nuclear, Anti-Ro/SS-
A, Anti-La/SS-B, Anti-smooth muscle, Anti-mitochondrial,
Anti-liver kidney, and Anti-neutrophil cytoplasmic anti-
bodies), serologies for HCV, Rickettsiae, Coxiella bruneti,
Brucella, Cryptococcal antigen, and Quantiferon TB-Gold.
All the blood tests resulted negative. Notably, most of the
patient's values of renal and tubular function (creatinine,
urine inorganic phosphate levels, urine calcium: urine
creatinine ratio) were within their normal ranges. So
were most of the markers of bone metabolism (see Table 1);
only the levels of 25-OH vitamin D3 were below the
physiological limits (9.4 ng/mL, normal values > 30 ng/mL).
We then planned a medication wash-out, together with
more detailed investigations: I) a lower left limb nuclear
magnetic resonance (NMR) without contrast enhancement
demonstrated focal alterations of the tibial diaphysis, likely
linked to an inflammatory process [Figure 1 Panel B]; II)
a contrast enhancement NMR of the lower extremities
revealed multiple millimetric contrast-enhanced cortico-
subcortical abnormalities in the left tibia diaphysis [Figure 1
Panel C]; III) a positron emission tomography - computed
tomography (PET-CT) with [18 F] FDG, performed on
June 2011, confirmed the presence of multiple areas of
increased uptake in the diaphyseal cortex of the left
tibia, that were not interpreted as neoplastic lesions but
rather as inflammatory results. [Figure 1 Panel D]; IV)
multiple bone biopsies (which showed focal necrosis
and remodeled lamellar bone tissue with interlamellar
spaces occupied by fibrosis and round-oval elements not
otherwise specified) were examined by two different and
independent pathologists, definitely excluding a malignant
disease.
The patient's clinical and biochemical conditions grad-
ually improved, so we decided to reintroduce a new anti-
retroviral therapy with lamivudine-abacavir and lopinavir/
ritonavir, opting for a TDF-free regimen. The patient
underwent a biochemical follow-up 4 months after the
Figure 1 Morphological and functional imaging of the patient's bone lesions. A: Anterior-posterior x-ray image: focal bone loss of uncertain
significance localized in the proximal and middle diaphysis of the left tibia. B: Sagittal and axial NMR images: focal alterations of the left tibia, both
in the medullar and in the cortical portion, probably related to an inflammatory process. C: Coronal and axial NMR images: contrast-enhanced
cortico-subcortical abnormalities in the middle-distal diaphysis of the left tibia. D: PET/CT fused images (coronal and axial): increased uptake of
FDG in the diaphyseal cortex of the left tibia associated with structural alterations probably connected to inflammatory results.
Table 1 Principal markers of bone metabolism at the time of hospitalization and at the 4-month follow-up
Normal range June 2011 October 2011
Total calcium, plasma (mg/dL) 8.5 – 10.3 9.1 9.4
Inorganic phosphate, plasma (mg/dL) 2.0 – 5.0 2.9 2.2
Bone alkaline phosphatase, serum (mcg/L) 6 – 30 19.2 11.2
Parathormone (PTH), plasma (pg/mL) 15.0 – 65.0 57.4 62.2
Osteocalcin, serum (ng/mL) 14 – 42 21 13
Beta-cross laps, plasma (pg/mL) < 584 336 256
25-OH Vitamin D3, serum (ng/mL) > 30 9.4 24.9
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hospitalization (Table 1), but refused further imaging
evaluations we proposed. He eventually recovered a
good viro-immunological profile and did not complain
about any osteo-articular pain thereafter.
Conclusions
The effect of tenofovir on the bone metabolism, especially
when used in combination with protease inhibitors,
is well demonstrated [8]. This iatrogenic impairment
occurs on a system already damaged by the persistent
immune activation due to HIV and by associated risk
factors [4-7]. The most frequent consequence is osteopor-
osis. In our case, however, despite the evident condition of
hypovitaminosis D, the normality of all the other labora-
tory tests (especially PTH and beta-cross laps, important
markers of bone remodeling) and the DEXA examination,
make the diagnosis of osteoporosis at least unlikely. So
were the hypotheses of secondary hyperparathyroidism
(given the values of the markers of bone metabolism,
Table 1) and of a tubular kidney disease, as we could
gather from the results of renal and tubular function
markers. In addition, the morphological and functional
imaging and the clinical presentation clearly suggest local-
ized inflammatory lesions.
The patient's positive response to the medication wash-
out and the absence of a disease relapse after the re-
introduction of HAART without tenofovir led us to
assume a central role of this drug in the onset of the
bone lesions. Our hypothesis is supported by the strong
clinical evidence on the effects of tenofovir on the bone
metabolism, and by the pathophysiology mechanisms of
TDF (which directly interacts with the osteoblast activity)
[1,4,5,9]. Yet the reason why the patient, with a stable
viro-immunological situation, showed this clinical picture
remains unclear. It can be thought that it happened when
the "osteoimmunological balance” in the immuno-skeletal
interface [6] had been altered.
We consider, therefore, our report noteworthy: this
possible side effect of tenofovir, although unusual, should
be taken into account in the differential diagnosis of an
HIV-positive patient with focal bone lesions.
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